AstraZeneca and Daiichi Sankyo: FDA OKs ENHERTU as first HER2-directed therapy for patients with HER2-low or HER2-ultralow metastatic breast cancer following disease progression after one or more endocrine therapies  $AZN, #AstraZeneca, #DaiichiSankyo